The acquisition of Sepranolone, a Phase 2b ready asset, positions Relmada Therapeutics to expand its pipeline into the treatment of Tourette syndrome and other compulsion-related conditions. This strategic move could enhance Relmada's market position and potentially lead to future revenue growth, positively impacting its stock price in the short term.